Class I Anti-cea Antibodies And Uses Thereof

Abstract

The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.


Claims
Owners (US)
CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Jun 25, 2013
  • Application: Sep 7, 2012
    US US 201213606899 A
  • Priority: Sep 7, 2012
    US US 201213606899 A
  • Priority: Jul 29, 2010
    US US 84606210 A
  • Priority: Sep 16, 2009
    US US 24287209 P

Download Citation


Sign in to the Lens

Feedback